Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678730 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacogenetics of Cannabinoid Response
A Early Phase 1 study of COMT Gene Polymorphism, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT00678730 is a Early Phase 1 study of COMT Gene Polymorphism that has completed, run by Yale University. The registered enrollment target is 72 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00678730, a Early Phase 1 study of COMT Gene Polymorphism, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".
Conditions Studied
Interventions
- DRUG delta 9 tetrahydrocannabinol
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2007-08-23 |
| Est. Completion | 2014-09-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00678730
The ClinicalTrials.gov registry entry for NCT00678730 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COMT Gene Polymorphism appearing as the primary indexed condition, and to 1 intervention - of which delta 9 tetrahydrocannabinol is the first listed.
NCT00678730 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00678730 about?
NCT00678730 is a clinical study titled "Pharmacogenetics of Cannabinoid Response". This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".
What is the current status of trial NCT00678730?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 72 participants. The study started on 2007-08-23. Estimated completion is 2014-09-11.
What conditions does trial NCT00678730 study?
This clinical trial studies the following conditions: COMT Gene Polymorphism.
What interventions are being tested in trial NCT00678730?
The interventions under investigation include: delta 9 tetrahydrocannabinol (DRUG).
Who is sponsoring clinical trial NCT00678730?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00678730 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.